Cargando…

Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation p.T632I

Approximately 15% of acral and mucous melanomas carry activating mutations in KIT oncogene. There is a diversity of spectrum of KIT mutations, with some of them rendering tumors responsive to imatinib, while others being imatinib-resistant or not studied yet. Here we present an acral melanoma patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Orlova, Kristina V., Yanus, Grigory A., Aleksakhina, Svetlana N., Venina, Aigul R., Iyevleva, Aglaya G., Demidov, Lev V., Imyanitov, Evgeny N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477486/ https://www.ncbi.nlm.nih.gov/pubmed/31043947 http://dx.doi.org/10.1159/000495782

Ejemplares similares

Hereditary cancer syndromes
por: Imyanitov, Evgeny N, et al.
Publicado: (2023)

KRAS, NRAS, BRAF, HER2 and MSI Status in a Large Consecutive Series of Colorectal Carcinomas
por: Martianov, Aleksandr S., et al.
Publicado: (2023)

Cytotoxic and targeted therapy for hereditary cancers
por: Iyevleva, Aglaya G., et al.
Publicado: (2016)

Integration of the blood test into the low-dose computed tomography lung cancer screening: reliable discrimination between malignant and non-malignant radiographic findings
por: Kuligina, Ekaterina S., et al.
Publicado: (2021)

Efficacy of lorlatinib in lung carcinomas carrying distinct ALK translocation variants: The results of a single-center study
por: Orlov, Sergey V., et al.
Publicado: (2021)

Lack of Response to Vemurafenib in Melanoma Carrying BRAF K601E Mutation
por: Moiseyenko, Fedor V., et al.
Publicado: (2019)

Rapid and Cost-Efficient Detection of RET Rearrangements in a Large Consecutive Series of Lung Carcinomas
por: Tiurin, Vladislav I., et al.
Publicado: (2023)

Preparation of Duplex Sequencing Libraries for Archival Paraffin-Embedded Tissue Samples Using Single-Strand-Specific Nuclease P1
por: Mitiushkina, Natalia V., et al.
Publicado: (2022)

Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives
por: Aleksakhina, Svetlana N., et al.
Publicado: (2021)

Revisiting multiple erroneous genetic testing results and clinical misinterpretations in a patient with Li-Fraumeni syndrome: lessons for translational medicine
por: Sokolova, Tatiana N., et al.
Publicado: (2021)

MON-309 Intratumoral Proliferation and Proinflammatory Macrophages in Obese and Non-Obese Patients with Different Molecular-Biological Types of Endometrial Cancer
por: Berstein, Lev, et al.
Publicado: (2019)

Markers of Lymphocytic-Macrophagal Infiltration and Their Association With the Receptor Phenotype and Proliferative Activity of Tumor Tissue in Various Molecular-Biological Types of Endometrial Cancer
por: Berstein, Lev M, et al.
Publicado: (2021)

SUN-133 Intratumoral Expression of Steroid Receptors, CD68+ Macrophages and Mdm2 in Different Molecular-Biological Types of Endometrial Cancer
por: Berstein, Lev M, et al.
Publicado: (2020)

PALB2 mutations in German and Russian patients with bilateral breast cancer
por: Bogdanova, Natalia, et al.
Publicado: (2010)

Imatinib Responsiveness in Canine Mast Cell Tumors Carrying Novel Mutations of c-KIT Exon 11
por: NAKANO, Yuko, et al.
Publicado: (2013)

Strong founder effect for BRCA1 c.3629_3630delAG pathogenic variant in Chechen patients with breast or ovarian cancer
por: Sokolenko, Anna P., et al.
Publicado: (2022)

632. Recurrent Pneumococcal Meningitis in Adults
por: Lauter, Carl, et al.
Publicado: (2018)

Cost-Efficient Detection of NTRK1/2/3 Gene Fusions: Single-Center Analysis of 8075 Tumor Samples
por: Romanko, Aleksandr A., et al.
Publicado: (2023)

The role of c-kit and imatinib mesylate in uveal melanoma
por: Pereira, Patricia Rusa, et al.
Publicado: (2005)

BRCA1 4153delA founder mutation in Russian ovarian cancer patients
por: Krylova, Nadezhda Yu, et al.
Publicado: (2006)

Unraveling the Mechanisms of Sensitivity to Anti-FGF Therapies in Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST) Lacking Secondary KIT Mutations
por: Boichuk, Sergei, et al.
Publicado: (2023)

Features of omental adipose tissue in endometrial cancer patients with ‘standard’ or ‘metabolically healthy’ obesity: associations with tumor process characteristics
por: Berstein, Lev M., et al.
Publicado: (2016)

Tumor irradiation may facilitate the detection of tumor-specific mutations in plasma
por: Kuligina, Ekaterina, et al.
Publicado: (2021)

High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients
por: Suspitsin, Evgeny N, et al.
Publicado: (2009)

Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H
por: Revheim, Mona-Elisabeth, et al.
Publicado: (2013)

PT632. Alteration of the effects of corticotropin-releasing factor on synaptic transmission in the dorsolateral bed nucleus of the stria terminalis of chronic pain model rats
por: Takahashi, Daiki, et al.
Publicado: (2016)

Comprehensive evaluation of the test for 5′‐/3′‐end mRNA unbalanced expression as a screening tool for ALK and ROS1 fusions in lung cancer
por: Mitiushkina, Natalia V., et al.
Publicado: (2022)

Correction to Lancet Haematol 2020; 7: e632–34
Publicado: (2020)

Inhibition of c-Kit Is Not Required for Reversal of Hyperglycemia by Imatinib in NOD Mice
por: Lau, Janet, et al.
Publicado: (2014)

Micro-RNA-632 down regulates DNAJB6 in breast cancer
por: Mitra, Aparna, et al.
Publicado: (2012)

TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours
por: Saito, Yurina, et al.
Publicado: (2019)

Nuclear KIT induces a NFKBIB-RELA-KIT autoregulatory loop in imatinib-resistant gastrointestinal stromal tumors
por: Hsueh, Yuan-Shuo, et al.
Publicado: (2019)

Large family with both parents affected by distinct BRCA1 mutations: implications for genetic testing
por: Sokolenko, Anna P, et al.
Publicado: (2009)

Discrimination between Complete versus Non-Complete Pathologic Response to Neoadjuvant Therapy Using Ultrasensitive Mutation Analysis: A Proof-of-Concept Study in BRCA1-Driven Breast Cancer Patients
por: Sokolenko, Anna P., et al.
Publicado: (2023)

“Lazarus Response” to Olaparib in a Virtually Chemonaive Breast Cancer Patient Carrying Gross BRCA2 Gene Deletion
por: Moiseyenko, Vladimir M, et al.
Publicado: (2018)

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT
por: Handolias, D, et al.
Publicado: (2010)

Sustained response to imatinib in patient with extraskeletal myxoid chondrosarcoma and novel KIT mutation
por: Jennings, Brooke, et al.
Publicado: (2021)

Response to Imatinib in a Patient with Double-mutant KIT Metastatic Penile Melanoma
por: BEAUDOUX, Olivia, et al.
Publicado: (2021)

First results from the Argon glow discharge cleaned test section 632
por: Calder, R, et al.
Publicado: (1974)

Long term behaviour of the gas desorption coefficient in the test sections 333 and 632
por: Calder, R, et al.
Publicado: (1974)

Cannot write session to /tmp/vufind_sessions/sess_6ktiv8mi97bnu5ceif8i5jenj4